Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.
BACKGROUND
There is a lack of consensus regarding the prognostic significance of ureteral versus renal pelvic upper tract urothelial carcinoma (UTUC).


OBJECTIVE
To investigate the association of tumor location on outcomes for UTUC in an international cohort of patients managed by radical nephroureterectomy (RNU).


METHODS
A retrospective review of institutional databases from 10 institutions worldwide identified patients with UTUC.


METHODS
The 1249 patients in the study underwent RNU with ipsilateral bladder cuff resection between 1987 and 2007.


METHODS
Data accrued included age, gender, race, surgical approach (open vs laparoscopic), tumor pathology (stage, grade, lymph node status), tumor location, use of perioperative chemotherapy, prior endoscopic therapy, urothelial carcinoma recurrence, and mortality from urothelial carcinoma. Tumor location was divided into two groups (renal pelvis and ureter) based on the location of the dominant tumor.


CONCLUSIONS
The 5-yr recurrence-free and cancer-specific survival estimates for this cohort were 75% and 78%, respectively. On multivariate analysis, only pathologic tumor (pT) classification (p<0.001), grade (p<0.02), and lymph node status (p<0.001) were associated with disease recurrence and cancer-specific survival. When adjusting for these variables, there was no difference in the probability of disease recurrence (hazard ratio [HR]: 1.22; p=0.133) or cancer death (HR: 1.23; p=0.25) between ureteral and renal pelvic tumors. Adding tumor location to a base prognostic model for disease recurrence and cancer death that included pT stage, tumor grade, and lymph node status only improved the predictive accuracy of this model by 0.1%. This study is limited by biases associated with its retrospective design.


CONCLUSIONS
There is no difference in outcomes between patients with renal pelvic tumors and with ureteral tumors following nephroureterectomy. These data support the current TNM staging system, whereby renal pelvic and ureteral carcinomas are classified as one integral group of tumors.
Raman
Jay D
JD
New York-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA. jraman@hmc.psu.edu
Ng
Casey K
CK
Scherr
Douglas S
DS
Margulis
Vitaly
V
Lotan
Yair
Y
Bensalah
Karim
K
Patard
Jean-Jacques
JJ
Kikuchi
Eiji
E
Montorsi
Francesco
F
Zigeuner
Richard
R
Weizer
Alon
A
Bolenz
Christian
C
Koppie
Theresa M
TM
Isbarn
Hendrik
H
Jeldres
Claudio
C
Kabbani
Wareef
W
Remzi
Mesut
M
Waldert
Mathias
M
Wood
Christopher G
CG
Roscigno
Marco
M
Oya
Mototsuga
M
Langner
Cord
C
Wolf
J Stuart
JS
Ströbel
Philipp
P
Fernández
Mario
M
Karakiewcz
Pierre
P
Shariat
Shahrokh F
SF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D007682:Kidney Pelvis / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D009392:Nephrectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012189:Retrospective Studies; D014513:Ureter / Q000473:pathology* / Q000601:surgery; D014523:Urethral Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D019459:Urothelium / Q000473:pathology*